Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
Lindsay Maguire, MD
Study ID
NCT06085937
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Ketamine — DRUG
    Patients will receive 0.2mg/kg of IV ketamine

Study Details

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Key Dates

Start date
May 1, 2024
Status verified
Apr 2026
Primary completion
Apr 30, 2026
Completion
Apr 30, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ketamine
    All patients will receive the experimental drug.

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 2 hours ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of Kansas Medical Center Emergency DepartmentKansas CityKansas66160
Lindsay Maguire, MD
[email protected]
8048144509
University of Kansas Strawberry Hill CampusKansas CityKansas66101
Tyler Kjorvestad, MD
[email protected]

Find similar trials in Kansas City, KS

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
University of Kansas Medical Center Emergency Department· Kansas City, KSUniversity of Kansas Strawberry Hill Campus· Kansas City, KS

Related Studies